17,261 trials
Non Small Cell Lung Carcinoma
Primary: Progression Free Survival — 2.3; 4.0; 2.4; 2.1 Months — p=0.24
Type 2 Diabetes Mellitus
Primary: Cognitive Outcome: Brief Visuospatial Spatial Memory Test -Total Recall (Unit T Score) — 39.46; 41.23; 43.1; 50.9 T-score
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 — 84.0; 89.7 percentage of participants
Cystinosis
Primary: Plasma Pharmacokinetic Parameter: Cmax of Cysteamine — 42.02; 33.06 umol/L
Bladder Cancer
Primary: Percentage of Participants That Respond to Treatment in Arm 1 and Arm 2 — 57.1; 61.4 percentage of participants
Brain and Central Nervous System Tumors · Sarcoma
Primary: Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment. — 15 Participants
Alveolitis · Systemic Sclerosis
Primary: Treatment-related Adverse Events — 5 participants
Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate — 38 percentage of participants
Diabetes Mellitus Type 2
Primary: Evaluate the Safety and Tolerability of ORMD-0801. — 0; 0; 0 Number of Events
Precancerous Conditions
Primary: Dose Escalation and Toxicity: Toxicities Including Grades 1 to 4 — 2; 2; 2; 1 participants
Asthma · Bronchospasm · Wheezing
Primary: Baseline Concentration (C0) of Total Epinephrine — 2.6; 4.3 pg/mL
Physiological Function in Low Oxygen Environment
Primary: Magnitude of Decrement in Exercise Time Trial Performance in Hypoxia (Low Oxygen) Compared With Normoxia (Normal Oxygen). — 22.3; 25.2; 22.2; 24.0 minutes
Partial Epilepsy
Primary: Change From Baseline in Power of Attention Score to the End of the Double Blind (DB) Period — 111.085; 59.122 Milli seconds (ms) — p=0.700
Hypoxia
Primary: Primary Objective Endurance Exercise Performance — 22.4; 24.5; 24.0; 24.6 minutes
Myelodysplastic Syndrome
Primary: Red Blood Cell Transfusion Independence — 6; 10; 21 participants